跳到正文
FDA 官方药品与生物制品信息·· 25 天前AI 评分27

FDA 生物类似药产品信息(截至2026年10月,含 Lucamzi、Zimrixby、Garzulys 等)

Biosimilar Product Information

AI 导读

FDA 生物类似药产品信息页面列出各生物类似药及其参照原研药,最新条目为2026年10月的 Lucamzi(ranibizumab-blrz),对应 Lucentis(ranibizumab)。

正文 · 原文

Lucamzi (ranibizumab-blrz)October 2026Lucentis (ranibizumab) Zimrixby (rituximab-cdxx)July 2026Rituxan (rituximab) Garzulys (insulin aspart-fsan)July 2026Novolog (insulin aspart)Garzulys InformationRanluspec (ranibizumab-hkdz)June 2026Lucentis (ranibizumab)Ranluspec InformationImmgolis and Immgolis Intri (golimumab-sldi)May 2026Simponi and Simponi Aria (golimumab)Immgolis and Immgolis Intri InformationEnnumo (pegfilgrastim-pccg)May 2026Neulasta (pegfilgrastim)Ennumo InformationLanglara (insulin glargine-aldy)April 2026Lantus (insulin glargine)Langlara InformationPonlimsi and Degevma (denosumab-adet)March 2026Prolia (denosumab)Ponlimsi Information
Degevma InformationFilkri (filgrastim-laha)January 2026Neupogen (filgrastim)Filkri InformationBoncresa and Oziltus (denosumab-mobz)December 2025Prolia and Xgeva (denosumab)Boncresa Information
Oziltus InformationNufymco (ranibizumab-leyk)December 2025Lucentis (ranibizumab)Nufymco InformationArmlupeg (pegfilgrastim-unne)November 2025Neulasta (pegfilgrastim)Armlupeg InformationPoherdy (pertuzumab-dpzb)November 2025Perjeta (pertuzumab)Poherdy InformationOsvyrti and Jubereq (denosumab-desu)October 2025Prolia and Xgeva (denosumab)Osvyrti and Jubereq InformationEydenzelt (aflibercept-boav)October 2025Eylea (aflibercept)Eydenzelt InformationEnoby and Xtrenbo (denosumab-qbde)September 2025Prolia and Xgeva (denosumab)Enoby and Xtrenbo InformationAukelso and Bosaya (denosumab-kyqq)September 2025Prolia and Xgeva (denosumab)Aukelso and Bosaya InformationBildyos and Bilprevda (denosumab-nxxp)August 2025Prolia and Xgeva (denosumab)Bildyos and Bilprevda InformationKirsty (insulin aspart-xjhz)July 2025Novolog (insulin aspart)Kirsty InformationStarjemza (ustekinumab-hmny)May 2025Stelara (ustekinumab)Starjemza InformationJobevne (bevacizumab-nwgd) April 2025Avastin (bevacizumab)Jobevne InformationBomyntra and Conexxence (denosumab-bnht)March 2025Prolia and Xgeva (denosumab)Bomyntra and Conexxence InformationOmlyclo (omalizumab-igec)March 2025Xolair (omalizumab)Omlyclo InformationStoboclo and Osenvelt (denosumab-bmwo)February 2025Prolia and Xgeva (denosumab)Stoboclo and Osenvelt InformationMerilog (insulin aspart-szjj)February 2025Novolog (insulin aspart)Merilog InformationOspomyv and Xbryk (denosumab-dssb)February 2025Prolia and Xgeva (denosumab)Ospomyv and Xbryk InformationAvtozma (tocilizumab-anoh)January 2025Actemra (tocilizumab)Avtozma InformationSteqeyma (Ustekinumab-stba)December 2024Stelara (ustekinumab)Steqeyma InformationYesintek (ustekinumab-kfce)November 2024Stelara (ustekinumab)Yesintek InformationImuldosa (ustekinumab-srlf)October 2024Stelara (ustekinumab)Imuldosa InformationOtulfi (ustekinumab-aauz)September 2024Stelara (ustekinumab)Otulfi InformationPavblu (aflibercept-ayyh)August 2024Eylea (aflibercept)Pavblu InformationEnzeevu (aflibercept-abzv) August 2024Eylea (aflibercept)Enzeevu InformationEpysqli (eculizumab-aagh)July 2024Soliris (eculizumab)Epysqli InformationAhzantive (aflibercept-mrbb)June 2024Eylea (aflibercept)Ahzantive InformationNypozi (filgrastim-txid)June 2024Neupogen (filgrastim)Nypozi InformationPyzchiva (ustekinumab-ttwe)June 2024Stelara (ustekinumab)Pyzchiva InformationBkemv (eculizumab-aeeb)May 2024Soliris (eculizumab)Bkemv Information
Press Release: FDA Approves First Interchangeable Biosimilar for Two Rare DiseasesYesafili (aflibercept-jbvf)May 2024Eylea (aflibercept)Yesafili Information
CDER Notable Approval: FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditionsOpuviz (aflibercept-yszy)May 2024Eylea (aflibercept)Opuviz Information
CDER Notable Approval: FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditionsHercessi (trastuzumab-strf)April 2024Herceptin (trastuzumab)Hercessi InformationSelarsdi (ustekinumab-aekn)April 2024Stelara (ustekinumab)Selarsdi InformationTyenne (tocilizumab-aazg) March 2024Actemra (tocilizumab)Tyenne InformationJubbonti and Wyost (denosumab-bbdz)March 2024Prolia and Xgeva (denosumab)Jubbonti and Wyost Information
CDER Notable Approval: FDA approves first interchangeable biosimilars to Prolia and Xgeva to treat certain types of osteoporosis and prevent bone events in cancerSimlandi (adalimumab-ryvk)February 2024Humira (adalimumab)Simlandi InformationAvzivi (bevacizumab-tnjn)December 2023Avastin (bevacizumab)Avzivi InformationWezlana (ustekinumab-auub)October 2023Stelara (ustekinumab)Wezlana Information
Press Release: FDA Approves Interchangeable Biosimilar for Multiple Inflammatory DiseasesTofidence (tocilizumab-bavi)September 2023Actemra (tocilizumab)Tofidence Information
CDER Notable Approval: FDA approves first biosimilar to Actemra to treat adult and pediatric arthritisTyruko (natalizumab-sztn)August 2023Tysabri (natalizumab)Tyruko Information
Press Release: FDA Approves First Biosimilar to Treat Multiple SclerosisYuflyma (adalimumab-aaty)May 2023Humira (adalimumab)Yuflyma InformationIdacio (adalimumab-aacf)December 2022Humira (adalimumab)Idacio InformationVegzelma (bevacizumab-adcd)September 2022Avastin (bevacizumab)Vegzelma InformationStimufend (pegfilgrastim-fpgk)September 2022Neulasta (pegfilgrastim)Stimufend InformationCimerli (ranibizumab-eqrn)August 2022Lucentis (ranibizumab) Cimerli InformationFylnetra (pegfilgrastim-pbbk)May 2022Neulasta (pegfilgrastim)Fylnetra InformationAlymsys (bevacizumab-maly)April 2022Avastin (bevacizumab)Alymsys InformationReleuko (filgrastim-ayow)February 2022Neupogen (filgrastim) Yusimry (adalimumab-aqvh)December 2021Humira (adalimumab)
Yusimry InformationRezvoglar
(insulin glargine-aglr)December 2021Lantus (insulin glargine)RezvoglarByooviz
(ranibizumab-nuna)September 2021Lucentis (ranibizumab)Byooviz Information 
Press Release: FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye ConditionsSemglee
(Insulin glargine-yfgn)July 2021Lantus (Insulin glargine)Semglee Information
Press Release: FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of DiabetesRiabni
(rituximab-arrx)December 2020Rituxan (rituximab)Riabni Information Hulio
(adalimumab-fkjp)July 2020Humira (adalimumab)Hulio InformationNyvepria
(pegfilgrastim-apgf)June 2020Neulasta (pegfilgrastim)Nyvepria InformationAvsola
(infliximab-axxq)December 2019Remicade (infliximab)Avsola InformationAbrilada
(adalimumab-afzb)November 2019Humira (adalimumab)Abrilada InformationZiextenzo
(pegfilgrastim-bmez)November 2019Neulasta (pegfilgrastim)Ziextenzo InformationHadlima
(adalimumab-bwwd)July 2019Humira (adalimumab)Hadlima InformationRuxience
(rituximab-pvvr)July 2019Rituxan (rituximab)Ruxience InformationZirabev
(bevacizumab-bvzrJune 2019Avastin (bevacizumab)Zirabev InformationKanjinti
(trastuzumab-anns)  June 2019Herceptin (trastuzumab)Kanjinti Information Eticovo
(etanercept-ykro)April 2019Enbrel (etanercept)Eticovo InformationTrazimera
(trastuzumab-qyyp)March 2019Herceptin (trastuzumab)Trazimera InformationOntruzant
(trastuzumab-dttb)January 2019Herceptin (trastuzumab)Ontruzant InformationHerzuma
(trastuzumab-pkrb) December 2018Herceptin (trastuzumab)Herzuma Information Truxima
(rituximab-abbs)November 2018Rituxan (rituximab)Truxima Information
Press Release: FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphomaUdenyca
(pegfilgrastim-cbqv) November 2018Neulasta (pegfilgrastim)Udenyca Information Hyrimoz
(adalimumab-adaz)October 2018Humira (adalimumab)Hyrimoz InformationNivestym
(filgrastim-aafi)July 2018Neupogen (filgrastim)Nivestym InformationFulphila
(pegfilgrastim-jmdb)June 2018Neluasta (pegfilgrastim)Fulphila Information
Press Release: FDA approves first biosimilar to Neulasta to help reduce the risk   of infection during cancer treatmentRetacrit
(epoetin alfa-epbx)May 2018Epogen (epoetin-alfa)Retacrit information
Press Release: FDA approves first epoetin alfa biosimilar for the treatment of anemiaIxifi (infliximab-qbtx)December 2017Remicade (infliximab)Ixifi informationOgivri
(trastuzumab-dkst)December 2017Herceptin (trastuzumab)Ogivri information
Press Release: FDA approves first biosimilar for the treatment of certain breast and stomach cancersMvasi
(Bevacizumab-awwb)September 2017Avastin (bevacizumab)Mvasi information
Press Release: FDA approves first biosimilar for the treatment of cancerCyltezo
(Adalimumab-adbm)August 2017Humira (adalimumab)Cyltezo information  Renflexis (Infliximab-abda)May 2017Remicade (infliximab)Renflexis informationAmjevita
(Adalimumab -atto)September 2016Humira (adalimumab)Amjevita information
Press Release: FDA approves AmjevitaErelzi
(Etanercept-szzs)August 2016Enbrel (etanercept)Erelzi information
Press Release: FDA approves ErelziInflectra
(Infliximab-dyyb)April 2016Remicade (infliximab)Inflectra information
Press Release: FDA approves InflectraZarxio
(Filgrastim-sndz)March 2015Neupogen (filgrastim)Zarxio information

来源:FDA 官方药品与生物制品信息 · fda.gov